Limited documentation exists on the effectiveness of psychoeducational group (PEG) versus support group (SG) interventions among breast cancer patients during primary care. Support group is a component of the hospitals’ routine breast cancer care.
The aim of this study was to investigate which of these approaches provides the greatest benefits to participants, particularly to women with low optimism (pessimists). The primary outcomes investigated here were anxiety, depression, and mental adjustment to cancer.
A total of 367 women with early-stage breast cancer were randomized to the PEG or SG intervention starting 1 to 8 weeks after surgery. The PEG intervention included health education, enhancement of problem-solving skills, stress management, and psychological support.
Participants in both groups showed improvement over time; however, no significant differences in emotional distress were found. The PEG participants exhibited more positive attitude at 2 and 6 months (P < .001) and less helplessness/hopelessness (P = .01) at 2 months compared with the SG participants. However, no significant differences were found between the groups at 12 months. Pessimists did not benefit more from attending the PEG than they did from attending the SG.
Both groups showed improvement in emotional distress and coping over time. Although the results were limited, the PEG intervention seems to enhance short-term, but not long-term, adaptive coping.
Psychoeducational group intervention yields benefits during the difficult period when patients receive adjuvant chemotherapy or radiotherapy. Thus, the hospital’s standard group interventions have been changed to include more health education and stress management, but within the same time frame as the original SG.
Authors Affiliations: Department of Oncology, Oslo University Hospital, Oslo (Drs Schou Bredal and Kåresen and Ms Sørensen); Faculty of Medicine, University of Oslo, Oslo (Drs Schou Bredal, Kåresen, and Smeby); Department of Acute Medicine, Oslo University Hospital, Oslo (Dr Ekeberg and Ms Espe); Breast Center, Vestfold Hospital, Vestfold, Norway (Ms Amundsen and Dr Aas); Department of Behavioral Sciences in Medicine, Faculty of Medicine, University of Oslo (Dr Ekeberg).
This study was partly funded by the Eastern Norway Regional Health Authority.
The authors have no conflicts of interest to disclose.
Correspondence: Inger Schou Bredal, PhD, RN, Department of Oncology, Unit for Breast and Endocrine Surgery, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway ( email@example.com).
Accepted for publication April 16, 2013.